Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Penchev VR, Chang Y-, Begum A, Ewachiw T, Gocke C, Li J, et al. Ezrin Promotes Stem Cell Properties in Pancreatic Ductal Adenocarcinoma. Mol Cancer Res. 2019;17(4):929-936.

Al-Kawaaz M, Sanchez T, Kluk MJ. Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas. J Hematop. 2019;12(2):57-65.

Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun. 2019;10(1):2977.

Sun L, Thorson T, Zhu R, Huo J, Tong J, Rodgers WH, et al. A case report of parotid mammary analogue secretory carcinoma and reviews. Int J Surg Case Rep. 2019;55:88-91.

Magruder M, Sholi AN, Gong C, Zhang L, Edusei E, Huang J, et al. Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection. Nat Commun. 2019;10(1):5521.

Acosta-Gonzalez G, Ouseph M, Lombardo K, Lu S, Glickman J, Resnick MB. Immune environment in serrated lesions of the colon: intraepithelial lymphocyte density, PD-1, and PD-L1 expression correlate with serrated neoplasia pathway progression. Hum Pathol. 2019;83:115-123.

Naccache SN, Callan K, Burnham CA, Wallace MA, Westblade LF, Bard JD. Evaluation of Oxacillin and Cefoxitin Disk Diffusion and Microbroth Dilution Methods for Detecting -Mediated β-Lactam Resistance in Contemporary Staphylococcus epidermidis Isolates. J Clin Microbiol. 2019;57(12).

Zhang Y, Zhou CK, Rencsok EM, Fall K, Lotan TL, Loda M, et al. A Prospective Study of Intraprostatic Inflammation, Focal Atrophy, and Progression to Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(12):2047-2054.

Labbé DP, Zadra G, Yang M, Reyes JM, Lin CY, Cacciatore S, et al. High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. Nat Commun. 2019;10(1):4358.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, et al. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clin Cancer Res. 2019;25(1):43-51.